Clinical Trials
26
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)ā¢ Click on a phase to view related trials
Global Reference Ranges - Singapore
- Conditions
- Healthy Participants
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Perspectum
- Target Recruit Count
- 50
- Registration Number
- NCT07166471
Haemdall: Developing a Quantitative MRI Biomarker of Infratentorial Superficial Siderosis of the Central Nervous System
- Conditions
- Superficial Siderosis
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Perspectum
- Target Recruit Count
- 50
- Registration Number
- NCT07098650
- Locations
- š¬š§
Perspectum, Oxford, United Kingdom
First-trimester Placental Ultrasound Study
- Conditions
- Fetal Growth ComplicationsPregnancy Complications
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Perspectum
- Target Recruit Count
- 4000
- Registration Number
- NCT05326191
- Locations
- š¬š§
King's College Hospital NHS, Fetal Medicine Foundation, London, United Kingdom
Research and Development of Novel Quantitative Magnetic Resonance Imaging (MRI) Techniques in a Single Scan for Multiple Organ Application
- Conditions
- Multiple
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Perspectum
- Target Recruit Count
- 200
- Registration Number
- NCT05110248
- Locations
- š¬š§
Gemini One, 5520 John Smith Drive, Oxford, Oxfordshire, United Kingdom
UK Imaging Diabetes Study Seeing Diabetes Clearly
- Conditions
- Type2 Diabetes
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Perspectum
- Target Recruit Count
- 1000
- Registration Number
- NCT05057403
- Locations
- š¬š§
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
Landmark Study Confirms Liver Health Biomarker cT1 Predicts Cardiac and Liver Outcomes
A major Nature Medicine study of 28,841 individuals demonstrates that Perspectum's iron corrected T1 (cT1) MRI biomarker effectively predicts both liver-related and cardiac outcomes, establishing it as a valuable non-invasive alternative to liver biopsy.
MRI Biomarkers Show Promise in Predicting Treatment Response in MASH, Reducing Need for Biopsies
ā¢ New research validates quantitative MRI imaging as a reliable alternative to liver biopsies for assessing disease and monitoring treatment response in MASH patients. ā¢ A reduction of 80ms in cT1, measured by Perspectum's LiverMultiScan, predicts histological response to MASH therapies, offering a non-invasive biomarker for clinical trials. ā¢ The studies highlight the potential of non-invasive tests (NITs) to track liver health changes, potentially reducing reliance on invasive liver biopsies in MASH drug development. ā¢ Perspectum's LiverMultiScan, an FDA-cleared technology, offers a comprehensive assessment of liver health by quantifying disease activity, severity, fat, and iron content.